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The 1990’s have witnessed the discovery of the 'endocannabinoid-cannabinoid (CB) receptor (ECBR) system' consisting of 
specific receptors (CB1 and CB2), at least 3 endogenous ligands (anandamide, 2-arachidonyl glycerol and noladin ether) and 
their enzymes. Subsequently, a series of discoveries were made on the involvement of the ECBR system in many physiological 
functions including immunity, inflammation, neurotoxicity and neurotrauma, epilepsy, depression and stress, appetite, food intake
and energy homeostasis, cardiovascular regulation, reproduction, and bone remodeling. The brain-gut-adipose axis regulates 
digestive processes, food ingestion and energy balance and is closely associated with hormonal regulation by the hypothalamic-
pituitary-adrenal stress axis and by the mesolimbic reward system. It is proposed to call these interfacing systems the “alimentary 
control system”. ECBR presence in brain, gastrointestinal as well as adipose tissue explains its role in food intake, digestion 
and the regulation of adipose tissue mass. Moreover, the ECBR system's involvement in stress and emotional processing, makes 
it eminently suited to be (one of) the principle players in the alimentary control system. The ECBR system is present during the 
early embryonal and postnatal stages and we have discovered endocannabinoids in maternal milk. The ECBR system seems 
to be of critical value for newborn milk ingestion and suckling. Ghrelin, an orexigenic gastric hormone, exerts many effects 
similar to those of endocannabinoids. Therefore this review will compare some of the functions and anatomy of ghrelin and 
endocannabinoids. It is concluded that (i) the ECBR system is a major mediator between the brain and the alimentary system, 
and possibly, the adipose tissue, (ii) the role of the ECBR system in adult regulation of food processing is a remnant of its critical 
role for the initiation of feeding in the newborn, and (iii) the pervasive influence of the ECBR system in alimentary control make
it a highly suitable target for therapeutic developments for pathophysiological conditions such as inflammatory bowel disease,
irritable bowel syndrome, gastric ulcers, nausea, anorexia and failure-to-thrive. Biomed Rev 2006; 17: 23-42.
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INTRODUCTION: THE "ALIMENTARY CONTROL SYSTEM"
Appetite, hunger and satiety are regulated by a number of 
hormonal signals emanating from the central nervous system 
(CNS), and upper gastrointestinal (GI) tract (GIT) and adipose 
tissue (1,2). Thus it is impossible to separate the appetite-hun-
ger-satiety signals which regulate food intake, from the diges-
tive processes in the GIT and the adipose tissue secretions such 
as leptin. Therefore in this review, regulation of food intake, 
appetite and the brain-gut-adipose system will be considered 
as one system regulating ingestion and digestion, and will be 
denoted the "alimentary control system".
The rich bidirectional interactions between the brain and 
the local neuronal network (the enteric nervous system - 
ENS) in the intestinal system (the 'brain-gut axis'), have been 
extensively studied. Thus, for example, psychological stress 
as well as transcranial stimulation of the cortex in humans, 
have been shown to affect gut activities such as secretion and 
motility (3). Conversely, using brain imaging techniques such 
as functional magnetic resonance imaging (fMRI) or positron 
emission tomography (PET), have shown that visceral sensa-
tion resulting from stimulation of the oesophagus, stomach or 
rectum, resulted in activation of higher brain centers including 
the somatosensory cortex, anterior cingulate cortex, thalamus, 
insula and prefrontal cortex (1,3-5). Moreover patients suffer-
ing from irritable bowel syndrome (IBS), displayed different 
response patterns (4). Relatively few animal studies have 
investigated the brain-gut associations in an integrative (bi-
obehavioral) way. The data that have been collected, however, 
are very intriguing. For example, traumatic brain injury caused 
intestinal dysfunction and affected concentrations of several 
brain/intestinal peptides such as vasoactive intestinal peptide 
(VIP) and cholecystokinin (CCK) in blood and intestinal tis-
sue (jejunum) (6). Further, secretin, a secretory gut hormone, 
which has also been suggested to ameliorate autistic symptoms, 
activated a number of brain areas as measured by c-fos gene 
expression in rat brain. These brain structures included not 
only the dorsal vagal complex structures which are part of the 
brain-gut axis, but also the prefrontal cortex, which is thought 
to play a role in autism (7). 
The brain-gut axis has been the subject of a number of 
recent reviews (3,5,8,9). Adipose tissue is now recognized as 
an endo- and paracrine secretory organ regulating a number 
of functions beyond lipid and energy homeostasis (reviewed 
in 10,11). Recently, the ECBR system has been shown to be 
fully represented and functional in adipocytes (12,13). In this 
review, we will examine the role of the relatively recently 
discovered endocannabinoids and their cannabinoid CB re-
ceptors (the 'ECBR system') (14,15) in alimentary control and 
adipocyte-regulated energy balance via the brain-gut-adipose 
system. Thus first, the major aspects of the alimentary control
system will be briefly outlined; next, the ECBR system will be
reviewed, after which its multiple role in alimentary control 
will be discussed. Finally, a brief discussion of developmental 
aspects of the ECBR system in alimentary control will be of-
fered followed by a comparison with the hormone ghrelin.
THE BRAIN-GUT-ADIPOSE AXIS AND THE ALIMENTARY 
CONTROL SYSTEM
Ingestion
Ingestion is controlled by a large number of interacting hor-
mones originating from the brain, GIT and adipose tissue.
Hormones from adipose tissue 
Leptin is a major adipocyte-derived hormone, its plasma 
concentrations being proportionate to body fat content and it 
enter the brain according to its plasma levels. Inside the arcuate 
nucleus of the hypothalamus, it regulates a number of peptides 
involved in energy control and food intake (11,16,17) (see 
below). Recently more than 100 adipose-secreted signaling 
proteins, collectively named adipokines, have been isolated 
and reviewed; many of these are pleiotropic (10,11). The 
present review will concern itself only with those which are 
pimarily associated with energy balance, including leptin and 
adiponectin. Additional adipokines, like nerve growth factor 
(NGF), which have many additional functions and locations, 
will be discussed in the appropriate sections.
Hormones from the GIT 
Cholecystokinins (CCK-8, CCK-33, CCK-39) activate CCK1 
receptors on vagal afferents to the nucleus of the solitary tract 
(NTS). Cholecystokinins also enters the bloodstream, reducing 
appetite directly in the hypothalamus (see below) (2,14,18,19). 
It is interesting to note that CCK has the ability to stimulate 
the synthesis of nerve growth factor (NGF), an adopokine 
(10) which is also found in additional peripheral tissue and 
in the brain, thus enhancing NGF-induced anti-inflammatory
activity (20).
Peptide tyrosine tyrosine (PYY) activates vagal Y2 
receptors, but also penetrates the brain through the median 
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eminence, reaching the hypothalamus, where it activates 
hypothalamic Y2 receptors. Plasma PYY levels rise almost 
immediately after the onset of a meal (2,21), thus suggesting 
a tight control mechanism on meal size.
Ghrelin is produced primarily by the stomach, but minor 
amounts are also made in the small intestine and hypothalamus 
(22). Endogenous ghrelin levels increase before a meal and fall 
almost immediately upon food intake, while exogenous ghrelin 
enhances food intake (2,21). Conversely, a ghrelin antagonist 
reduced food intake and body weight in mice (23). In addition 
to appetite and weight control, ghrelin enhances intestinal 
motility, acid secretion and conveys mucosal protection (2). 
It also fulfills other physiological roles such as cardiovascular
and sleep regulation (22). In view of its rapid response to the 
commencement of food intake, ghrelin is thought to play a 
major role in the initiation of food intake (2) (see Table 2). 
Exogenous ghrelin almost tripled food intake and decreased 
plasma leptin by 30%. The suppression is mutual ('ghrelin-
leptin tango') (2,24).
Orexin A and B are found in the gut and enhance food 
intake by inhibiting vagal afferent discharge, thus negatively 
interacting with the anorexic effects of CCK (2)
Hormones in the brain
Many of the GI hormones including those mentioned in the 
previous section are also synthesized in the CNS, where they 
directly influence appetite and also have additional functions
(18,22,25,26). However, several hormones are particularly 
involved in the central neural network responsible for the regu-
lation of food intake and these are briefly described below.
The adipocyte-secreted hormone leptin, entering the brain 
from the blood circulation, is a major regulator of a number 
of peptides located in the arcuate nucleus of the hypothala-
mus. There, leptin inhibits orexigenic peptides (neuropeptide 
tyrosine, NPY, and agouti-related potein, AgRP) and simul-
taneously, activates the anorexigenic precursor molecule 
proopiomelanocortin (POMC) (27). An increase in POMC 
in turn, produces enhanced levels of its cleavage product, α-
melanocyte-stimulating hormone (α-MSH). Cocaine-and-am-
phetamine-regulated transcript (CART) which is colocalized 
with POMC in arcuate nucleus neurons, is also stimulated by 
leptin, eventually suppressing food intake (16,17,28). CCK, a 
satiety-inducing peptide previously found in the gut, directly 
signals satiety through its receptors in several feeding centers 
of the hypothalamus (arcuate nucleus, lateral hypothalamus 
and paraventricular nucleus (PVN) (29,30).
Additional CNS molecules which have been implicated in 
alimentary control include the neurotransmitters serotonin (5), 
GABA (31), and the opioid neuropeptides (32). However, an 
exhaustive discussion of such molecules is beyond the scope 
of this review. 
Digestion
The gastrointestinal tract has an independent nerve center (the 
enteric nervous system, ENS, or "gut brain") which maintains 
bilateral neural communication with the CNS along the nerves 
of the sympathetic and parasympathetic systems (2,5). Under 
normal conditions CNS control is minor. However, when 
homeostasis is perturbed such as in digestive disorders or dur-
ing psychological stress, CNS control plays a major role (5).
Gastrointestinal tract activity (mainly secretory and motor 
functions) is regulated via a 3-tier loop system (see ref. 2,5): (i) 
short (local ENS) loop, relying on independent ENS activity, 
(ii) spinal cord-reflexes, via the autonomic (sympathetic and
parasympathetic systems), and (iii) via the brain: a number of 
brain regions play a role and/or are influenced by the GIT: the
first target region is the brainstem, where vagal afferents target
the nucleus of the solitary tract (NTS), adjacent to the dorsal 
motor nucleus of the vagus (DMV). Via interneurons connect-
ing the NTS with the DMV, a long vago-vagal neural reflex
loop is established. In addition, part of the intestinal neural 
input to the NTS is transmitted further to the hypothalamus (the 
paraventricular nucleus [PVN] and the arcuate nucleus), and 
further to the amygdala, the bed nucleus of the stria terminalis 
(BNST) and ventral thalamus (2). Cortical areas, including the 
anterior cingulate cortex, somatosendory cortex, and prefrontal 
cortex, have been shown to represent GI sensations (1,3,5). 
Notably, several if these structures (amygdala, hypothalamus, 
cingulate and prefrontal cortices) are part of the limbic system 
for emotional processing (28).
EMOTIONAL STRESS AND THE ALIMENTARY CONTROL 
SYSTEM
As stated above, gastrointestinal functions are regulated by 
both the local ENS as well as by the CNS, the latter becoming 
more dominant when homeostasis is perturbed (5). It is well 
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known that emotional processes including stress and depres-
sion influence food intake (33,34) as well as GI functioning,
by for example, inhibiting gastric emptying and stimulating 
GI motility (35,36). Interestingly, it has now been shown with 
brain imaging methods, that the limbic (emotional) system 
structures, the anterior cingulate cortex and prefrontal cortex, 
are activated during visceral pain, while patients with irri-
table bowel disease display a different pattern of activation 
(4,37). 
Corticotrophic releasing hormone (CRH), which is the 
hypothalamic hormone first in line in the series of hormones
released by the hypothalamic-pituitary-adrenal (HPA) axis 
upon stress exposure, is an important mediator of stress-in-
duced regulation of GI functioning (35). Thus the HPA and 
brain-gut-adipose axes are closely interrelated; it even has 
been suggested that the HPA axis is the hormonal arm of the 
brain-gut system (34). Indeed, traditionally, and still in various 
regions of the globe, food deprivation is a primary threat to 
survival and logically, food searching and the motivation for 
food ingestion, should be driven by hunger- and food depri-
vation-induced stress. Such integrative approach to feeding 
mechanisms (34) is supported by the neuranatomical and 
functional associations and overlap between the brain areas 
regulating stress responsivity and the alimentary system. 
Thus the limbic (emotional) system, including the hypotha-
lamus, amygdala, anterior cingulate cortex and the prefrontal 
cortex, also contains the focal CNS structures which direct 
GIT activities such as GI motility and gastric emptying (1). 
Functionally, CRH induces an anxiogenic response, but also 
participates in the stress-induced alterations in upper GIT and 
gastric motility (35). Conversely, the gastrin-releasing peptide 
(GRP) and its receptors, appear to be necessary for the memory 
of traumatic memories through their location in the amygdala 
(38). Additionally, a number of molecules including unicortin, 
CCK, ghrelin and the melanocortin product of POMC, which 
all regulate appetite and/or GI function, also influence emo-
tional processes (22,39,40).
REWARD AND THE ALIMENTARY CONTROL SYSTEM
As noted above, increased levels of the anorexigenic precur-
sor molecule POMC (27) results in enhanced production of 
α-MSH thus contributing to the suppression of food intake 
(16,17,28). Additional products of POMC are the opioids, 
which are intimately involved in the regulation of reward in the 
dopaminergic mesolimbic system (a neural pathway projecting 
from the ventral tegmental area in the midbrain to the forebrain 
nucleus accumbens (28,34)). The dopamine system, in turn, 
has been associated with food-related behaviors in humans 
(41). In rats, POMC neurons were inhibited after the nucleus 
accumbens shell was manipulated to elicit feeding behavior 
in rats (42). Thus, POMC’s involvement in both food intake 
(43) and reward may be part of the rewarding qualities of food 
ingestion. An additional important observation was made in 
a self-stimulation paradigm, where the stimulating electrode 
was placed in the lateral hypothalamus of food-restricted rats. 
Thus whereas, replicating previous data (44), food restriction 
enhanced self stimulation, administering leptin to such rats, 
decreased self stimulation. Together with the multitude of 
orexigenic and anorexigenic peptides which activate and/or 
reside in the nuclei of the lateral hypothalamus (including 
NPY, α-MSH, ΑgRP, CART, orexin, MCH) these observa-
tions strongly suggest that the reward/incentive value of food 
plays a major role in feeding and body weight regulation and 
has far reaching implications for addictive patterns of food 
intake (45). As outlined above, higher brain centers including 
the prefrontal cortex (PFC), have also been implicated in the 
neural circuits comprising the brain-gut axis, while the PFC 
also comprises an important component of the reward/ad-
diction system (46,47). This anatomical overlap between 
alimentary control and incentive/reward processing further 
supports common ground for feeding behavior, metabolism, 
and emotional processing of reward and addiction. Thus all of 
these processes need to be taken into account when designing 
strategies to combat abnormal feeding behaviors such as seen 
in obesity and anorexia nervosa. 
THE ENDOCANNABINOID-CB RECEPTOR SYSTEM 
Cannabinoid CB receptors 
Thus far two CB receptors, CB1 and CB2, have been identi-
fied and cloned (48-50). In addition, 2 splice variants to the
"classical" CB1 receptor have been identified (51-53). Widely
different lines of evidence suggest the existence of an ad-
ditional (or several additional) CB ("CBx", or "CB3") recep-
tors (54-56). The CB1 and CB2 receptors both belong to the 
superfamily of G-protein-coupled receptors (57). The CNS 
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concentrations of the CB1 receptor in general, reach levels 
similar to those of GABA- and glutamate-gated ion channel 
receptors (57). At the single cell resolution, high CB1 receptor 
mRNA expressing neurons in mouse forebrain were found to 
be mostly GABAergic, while most low CB1 expressing cells 
were not (58). In the same study, very high co-expression 
with the neuromodulator CCK was found in limbic as well 
as non-limbic cortical neurons. Since brain CCK and CBs 
act usually in opposite directions (59), the ECBR and CCK 
systems may conduct cross talk in their regulation of a number 
of physiological or pathophysiological functions including 
learning and memory (60), food intake (2) and schizophrenia 
(58,61). CB1 receptor mRNA is generally found at about 10-
fold lower levels in peripheral tissues than in the CNS (53). 
The CB2 receptor is generally found in non-neural, mostly 
immune tissue (57,62,63) but also in the GIT (53,64,65) (also 
see below). Recently, CB2 receptors have been discovered in 
neural cells throughout the brain. Perhaps the reason for their 
belated detection on neurons of the CNS, is their appearance 
in relatively low concentrations (66,67). 
Endocannabinoids and their enzymes
Several endocannabinoids (ECs) have been discovered thus 
far, all derivatives of arachidonic acid (14). The apparently 
major and most thoroughly studied ECs are anandamide (AEA) 
(68) and 2-arachidonyl glycerol (2-AG) (69). Additional ECs 
include noladin ether (64), N-arachidonoylglycerol dopamine 
(NADA) (70,71); virodhamine is thought to be a partial ago-
nist/antagonist on CB1 receptors (72). Noladin ether, NADA 
and virodhamine have not been systematically studied for 
their presence in the alimentary control system except for 
our observation that noladin ether inhibits intestinal motility 
in mice (64).
Up-to-date information on the synthesis, release, reuptake 
and degradation mechanisms for the ECs has been reviewed 
(73). In short, ECs are synthesized "on demand". This con-
cept is strongly supported by a positive relationship between 
EC production and intracellular calcium concentrations. 
Anandamide is synthesized mainly from N-arachidonylphos-
phatidyl-ethanolamine using the enzyme phospholipase-D. 
2-AG is enzymatically formed with diacylglycerol lipases α 
and β. The degradation of AEA is catalyzed by fatty acid amide 
hydrolase (FAAH). On the other hand, 2-AG can be broken 
down by several pathways: primarily by monoacylglycerol 
lipase (MAGL) but also by FAAH, by an esterification pathway
Location Effect Selected references
CNS-forebrain including 
hypothalamus
Rewarding/Stress effect on 
food intake and digestion;
Orexigenic effect
74,76-78





Mouth Salivation decreased 91
Lower esophageal sphincter Relaxation 85,92
Stomach Decreased gastric secretion 93




Table 1. Levels of alimentary control by the ECBR system 
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and by Cox-2 together with PGE synthase, transforming it to 
PGE2-glyceryl ester. Uptake and release of  ECs is probably 
regulated by a common transport system, although these 
mechanisms remain to be fully elucidated (73).
THE ECBR SYSTEM AND THE ALIMENTARY CONTROL 
SYSTEM
The multifaceted involvement of the ECBR system in alimen-
tary control will be discussed in the present section.  Thus 
it appears that the ECBR system plays a role at every level 
of alimentary control including reward/addiction and stress. 
Therefore, the remainder of this article will be devoted to 
ECBR involvement in alimentary control in health and dis-
ease and in the neonatal organism. Finally, the extent of the 
ECBR involvement in in-and digestion will be compared to 
functions of the ghrelin peptide, another recently discovered 
and apparently multileveled player in alimentary control and 
other physiological systems.
Cannabinoid CB1 receptors in alimentary control
Forebrain, reward and stress 
Components of the ECBR system are present in most struc-
tures throughout the brain (14,57), including the nucleus 
accumbens, the target area of the dopaminergic mesolimbic 
"reward" system (74). Importantly, CB1 receptors are co-
localized with dopamine receptors in the mouse forebrain 
(75). Not surprisingly then, 2-AG directly administered to 
the nucleus accumbens of the mesolimbic system, induced 
profound hyperphagia (76). These findings strongly suggest
a role for the ECBR system in regulating food intake through 
the incentive value of food.
A role for the ECBR system in the ability to cope with stress 
has been studied using behavioral and biochemical (77-79) 
techniques. Further, endocrinologically, ECs influence the HPA
stress axis at the pituitary and hypothalamic levels (77,79-81). 
As outlined above, the HPA stress axis strongly influences both
feeding and digestion. Therefore, the ECBR system may be 
expected to exert part of its influence on alimentary control
through the stress-regulating HPA axis. 
 The forebrain is also the interactive site for the ECBR system 
and other alimentary control hormones. Thus the orexigenic 
effect of local infusion of ghrelin into the hypothalamic PVN 
of rats, was abolished by a peripheral injection with rimona-
bant (82). These data suggest that hypothalamic ghrelin and 
CB1 receptors interact as part of a finely tuned system aimed
at maintaining balanced food intake. As mentioned above, 
the gut and brain peptide CCK induces a feeling of satiety 
mainly after its release in the gut by protein and fat digests (2). 
However, CCK is also highly coexpressed with CB1 receptors 
in brain structures including the cerebral cortex, hippocampus 
(58) and the amygdala (83). As noted above, the limbic brain 
plays a role in emotional aspects of food intake and appetite. 
It has also been noted that CCK and the ECBR system often 
signal in opposite directions (59). Therefore, it is plausible to 
expect that the ECBR and CCK systems interact with respect to 
food intake, appetite and satiety through emotional regulation 
in the limbic system. Coexpression of CCK (29,30) and CB1 
receptors in feeding-related nuclei of the hypothalamus has 
not specifically been studied. Therefore, cross-talk between
the CCK and ECBR systems at the hypothalamic level should 
also be examined.
Hindbrain
Evidence has accumulated that CB1 receptors are located in 
the dorsal vagal complex in the brainstem, comprising the 
area postrema, nucleus of the solitary tract (NTS) and dorsal 
motor nucleus of the vagus (DMV). From these locations it 
is thought now that the CBs mediate their antiemetic effects 
and relaxation of the lower oesophagal sphincter (LOS) (84-
86) and inhibition of gastric motility (87) and gastric acid 
secretion (84). 
It was also suggested that CBs may enhance appetite by 
suppression of inhibitory synapses in the DMV (88). In support 
of this assertion, CB1 receptors are coexpressed with CRH and 
CART in a significant proportion of neurons of the PVN and/or
DMV/lateral hypothalamus of mice (89). Likewise, neuronal 
CB2 receptors in the CNS have now been demonstrated in 
number of structures including cerebellum, cerebral cortex, 
hippocampus, brain stem and more (66,67). Their functional 
presence with respect to the brainstem, notably in the DMV, 
was investigated functionally. Thus evidence was found that 
CB2 receptors participate together with CB1, in the suppres-
sion of the emetic response (66). Such cooperation with CB1 
receptors would explain how much lower levels of CB2 re-
ceptors (1.5% of those present in spleen ref. 66,67), can be of 
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functional importance.
Vagus
CB1 receptors are present in the peripheral vagal afferent nerve 
endings in the nodose ganglion to influence visceral perception
(84,85). Also at this location CB1 receptors are co-expressed 
with CCK receptors, thus suggesting that, in addition to central 
interactions, the ECBR system interacts with the CCK system 
to regulate food intake and satiety in the periphery (90). 
Mouth
Very recently, functional CB1 and CB2 receptors have been 
identified in rat saliva. Thus activation of these CB receptors
reduced saliva secretion (91). Therefore it is possible that CB 
receptors play a role in digestion from the first stage of the
process.
Lower oesophageal sphincter
CB1 receptors are located in the lower oesophageal sphincter 
(LOS) muscle (84). Cannabinoid ligands (∆9-THC, WIN 
55,212-2) inhibited its relaxation in ferrets and dogs, thereby 
counteracting gastroesophageal acid reflux (85,92). These
studies also suggested however, that this effect is mediated by 
CB1 receptors in the dorsal vagal complex of the hindbrain.
Stomach
CB1 receptors are also present in gastric muscle and mucosa 
where they are localized in pre- and postganglionic cholinergic 
neurons (93). Izzo’s group (94), investigating CB1 receptor 
concentrations throughout the GIT, confirmed that concentra-
tions are highest in the stomach and in the colon. CB2 receptor 
mRNA has also been demonstrated in rat gastric tissue (95). 
Intestines
CB1 receptors are widely present in the GIT (96). The colon 
(together with the stomach as mentioned above) has the highest 
CB1 receptor density in the GIT (94). CB1 receptors are widely 
present along the GIT as studied in rats, mice and guinea pigs 
(see (97)). Thus CB1 receptors were found on cell bodies and 
fibers in myenteric plexus of cholinergic sensory, interneuronal
and motor neurons. In the submucosal plexus CB1 receptors 
are colocalized with VIP and NPY (98). These findings are
consistent with the influential role of the CBs on both secretory 
activity and motility of the gut (97). CB1 receptors have also 
been shown to mediate the inhibition gastric emptying (99) and 
intestinal transit/motility (100-102). Moreover, from the data 
collected thus far it seems that to a great extent intestinal CB1 
receptors located on extrinsic neurons, by inhibiting the release 
of acetylcholine (Ach), are responsible for CB-directed regula-
tion of secretory patterns and motility under normal conditions 
(103). However, it has been suggested that in pathophysi-
ological states, CB1 receptors located on intrinsic submucosal 
neurons are mobilized (84). Thus in an in vivo study, Izzo and 
colleagues demonstrated that cholera toxin-induced intestinal 
fluid accumulation, resulting in diarhoea, was inhibited by
the CB1 receptor agonist CP 55,940. This effect was not pre-
vented by ganglionic blockade with chlorisondamine (104). 
The importance of CB1 receptors in protecting the organism 
against inflammation of the GI system was demonstrated in
a study where CB1 receptor knockout mice were found to be 
more susceptible to experimentally induced colitis compared 
to controls; conversely, mice lacking the FAAH enzyme (thus 
presumably having higher levels of ECs), had greater protec-
tion against inflammatory agents (105).
A role for CB2 receptors in gastrointestinal activity was only 
recently fully accepted. An earlier report on CB2-mediated 
effects (by the CB2-selective agonist HU-308) on defecation 
in mice (64), was followed by many negative reports on a role 
for CB2 receptors in GI functions (96,97,106). For example 
croton oil-stimulated gastrointestinal transit was inhibited by 
WIN 55,212-2; this effect was reversed by rimonabant but not 
by the CB2 receptor antagonist SR144528, indicating a CB1 
receptor-mediated inhibition of gastrointestinal transit (101). 
However, more recent reports indicated that while during 
resting conditions, CB2 receptor agonists did not affect gas-
trointestinal transit in rats, acceleration of intestinal motility 
was reduced by CB2, and not by CB1 receptor activation after 
stimulation with lipopolysaccharide (LPS) (65). Although 
the issue needs further clarification, the accompanying com-
mentary to this report was aptly entitled "Cannabinoids and 
intestinal motility: welcome to CB2 receptor" (106). 
Adipose tissue
As indicated above, leptin is one of the first adipokine to be dis-
covered. Several years ago, Di Marzo, Kunos and colleagues 
(107) showed for the first time a link between leptin and the
ECBR system. Thus they reported that leptin injection to rats 
reduced concentrations of AEA and 2-AG. In the same study, 
elevated levels of ECs were found in mice (ob/ob and db/db) 
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and rats (Zucker) which display inherent impairments of the 
leptin system (107). Subsequently, CB1 receptors have been 
detected in animal adipose tissue (89,108,109), while the full 
set of ECBR system components (CB1 receptors, AEA and 2-
AG, synthesizing and degrading enzymes) has recently been 
described in human adipose tissue (12). In a different study, 
CB2 receptors were also detected on human adipose cells 
(110). Importantly, CB1 receptor knockout mice have less 
adipose tissue than wild type controls (89) and CB1 receptors 
are dysregulated in human abdominal obesity (109). 
The “classical”, Rita Levi-Montalcini’s neurotrophin NGF 
was recently introduced into the growing list of adipokines 
(10,11). Biology of NGF may be regulated by CB receptors, 
although thus far evidence for an interaction between NGF and 
the ECBR system has been shown only in nonadipose tissue. 
Thus, NGF receptor tropomyosin-related kinase A (TrkA) 
activation-induced inflammatory hyperalgesia was shown
to be mediated by EC stimulation of CB1 and CB2 receptors 
on peripheral nerves (111). Further, interactions between 
(endo)CBs and NGF and/or brain-derived nerve growth factor 
(BDNF) have been proposed for the regulation of reward/ad-
diction (112), pain processing (113) and cancer control (114). 
Recent evidence suggest that NGF/BDNF and the ECBR 
system interact in their modulation of brain plasticity, and 
emotional processes (112,115). Interestingly, NGF/BDNF have 
been associated with autism (116), while plasma NGF level 
were significantly raised in subjects classified as being in the
first stage of romantic love (117). Thus it will be interesting
to further investigate reciprocal relationships between these 
adipokines in the regulation of emotions/addiction, stress and 
social interaction. Furthermore, interactions between between 
NGF/BDNF and the ECBR system at the level of the adipose 
tissue should be addressed. 
Adiponectin is another example of multifunctional adi-
pokines (10,11,108,118-120). Plasma adiponectin levels, like 
those of NGF/BDNF (10), and differently from many other 
adipokines such as leptin, tumor necrosis factor-α and resistin 
(119), are reduced in patients with obesity and related cardi-
ometabolic diseases (118,119). Interestingly, weight reducing 
effects of the CB1 receptor antagonist/inverse agonist rimona-
bant was accompanied by enhanced levels of adiponectin in 
animal (108) as well as human (120) studies. 
Endocannabinoids in alimentary control
AEA-induced inhibition of defecation in mice was the first
report that ECs influence intestinal function (121). The ECs
AEA and 2-AG have been detected in the small intestine and 
colon (97,100,122). Overall, the ECs are present in the GIT at 
several-fold higher concentrations than in the brain (100,123) 
and are physiologically active (122). Additionally, the degrad-
ing enzymes and uptake transporters for the ECs have been 
located in the GIT (100,122,124). 
Two aspects of EC functioning in the alimentary system 
await final clarification.
1. Are the EC’s constitutively active, or only when stimulated 
(such as in pathophysiological conditions)? It appears that 
both situations exist, depending on factors including genetic 
and species differences. For example, rimonabant induced 
emesis by itself in the shrew but not in the ferret. This spe-
cies difference maybe explained by a higher constitutive 
level of ECs in shrews than in ferrets, in which the emetic 
stimulus may have to enhance EC concentrations before 
an emetic effect of rimonabant can be revealed (125,126). 
Further, cholera-toxin-induced fluid accumulation in the
mural intestine, was accompanied by upregulated CB1 
receptor mRNA and elevated levels of AEA (104). 
2. At least some of AEA’s effects are mediated by non-CB 
receptors, some of which are known and some are not yet 
defined (55). For example, AEA activates TRPV1 van-
nilloid receptors (127). Thus, although exogenous CBs, 
acting via CB receptors, have anti-inflammatory effects
in the GIT similarly to their effect in other systems and 
organs, application of the ECs AEA and 2-AG resulted in 
pro-inflammatory effects via TRPV1 receptors (128). Thus 
the 'duplicity' of the ECs as endovannilloids/ECs (129) sug-
gests a complex role of the ECs in inflammatory states of
the GIT. Furthermore, AEA inhibits, probably by allosteric 
modulation, serotonin 5-HT3 receptor activation (130,131) 
and activates at least one nonCB1-nonCB2 cannabinoid 
receptor ("CB3") (54-56).
Concluding this section, it clear that every level of the 
alimentary tract is affected by the ECBR system. Strikingly, 
ECBR influence on ingestion, digestion and emesis is always,
at the organismic level, in harmony (see also Table 1). Thus 
(endo)CBs reduce intestinal and gastric motility, gastric acid 
secretion, emesis and nausea, are anti-diarrheal and enhance 
appetite. Conversely, CB1 receptor antagonists cause emesis, 
anorexia and enhanced motility. 
Future studies will have to address the relative importance 
of the various levels of ECBR involvement in alimentary 
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control, such as CNS-directed influence, compared to direct
modulation by gastrointestinal/ENS sites. Izzo and colleagues 
have started to address this issue when they compared ED50-
values of the CB receptor agonist WIN55,212- and can-
nabinol-induced inhibition of intestinal transit after central 
(intracerebroventricular, icv) versus peripheral (intraperitoneal, 
ip) injections. ED50 values were significantly, but not dramati-
cally lower when injected icv. This prompted the authors to 
suggest that CB inhibit GI transit by both routes. However, 
after croton-oil-induced diarrhea, there were no differences in 
ED50 values of icv or ip injected CBs. Moreover, ganglionic 
blockade with hexamethonium did not affect the inhibitory 
effect of ip injected CBs (101). In a subsequent study, the same 
group showed that after croton oil, intestinal CB1 receptors 
were upregulated and that EC levels were not changed while 
the FAAH enzyme appeared at higher concentrations. These 
observations suggested that during inflammatory/diarhoea
states, the local gut ECBR system is upregulated (100), appar-
ently to reduce diarhoea and inflammation. Thus a dominantly
peripheral response to pathological states by the ECBR system 
contrasts with the impression that in general in the brain-gut 
axis, CNS control plays a more major role when homeostasis is 
perturbed such as in digestive disorders or during psychologi-
cal stress (5). Future studies will hopefully address the brain 
versus gut division of ECBR system labor in more detail.
Overall, the unified activity makes the ECBR system in the
alimentary control system exquisitely suitable for multi-lev-
eled treatment of syndromes such as irritable bowel syndrome 
and cachexia/anorexia, using ECBR-activating agents (84) or 
obesity/metabolic syndrome, using ECBR-inhibitors (132). A 
discussion of CB-based treatment of the metabolic syndrome/
obesity is beyond the scope of this review and the reader is 
referred to previous publications (132-134). However, some 
of the promising approaches to treating GIT discomfort and 
disease, are presented in the next section.
BRAIN-GUT BIDIRECTIONAL CONTROL VIA THE ECBR 
SYSTEM IN PATHOPHYSIOLOGICAL AND PSYCHOSOMATIC 
CONDITIONS
The ECBR system, as described above, is strongly represented 
in both brain and gut, or, more precisely in the CNS, in the 
dorsal vagal complex and at almost all levels of the gastroin-
testinal tract. Especially its involvement in stress and emotional 
processing make the ECBR system an excellent candidate to 
study both as an underlying cause for pathological and psy-
chosomatic problems of the digestive system as well as, as a 
target for new therapeutic approaches. Only conditions with a 
stress/psychosomatic component are considered here. 
Irritable bowel syndrome. There is little doubt that stress 
and the HPA axis play a major role in IBS symptomatology. 
Experimentally, upregulation of CRH receptors in the PVN 
and locus ceroeleus have been shown after colonic stimulation 
(135). The role of cortisol in IBS has also been demonstrated 
although its levels may be up- or down-regulated depending 
on perhaps, the type of patients and conditions (36,136). This 
is in agreement with our own findings that low levels of cor-
ticosterone may signify decreased stress coping capability in 
mice (77). Solid evidence exists for an (endo)CB-regulated 
reduction of intestinal motility (121,122,137,138) through 
CB1 (100) and CB2 (65,121,139) receptors. This property of 
ECBR has been proposed to be beneficial for IBS which is
often characterized by enhanced intestinal motility and con-
tractility (122,124).
Inflammatory bowel disease (IBD). Inflammatory bowel
diseases, including Crohn's disease and ulcerative colitis, 
result from inflammatory processes in the intestine and is
characterized by ulcers, rectal bleeding diarrhea, nausea and 
lack of appetite (124). Major life stresses are thought to in-
fluence disease activity in IBS, while a role for minor daily
stressors in IBD expression needs further investigation (36). 
In an animal model for Crohn's disease (orally applied croton 
oil to mice which causes inflammation in the small intestine),
a beneficial, slowing effect of CBs on intestinal motility has
been shown (100,101). This effect was apparently peripherally 
mediated (in the gut). Therefore such treatment is promis-
ing when central/psychological treatment is not likely to be 
helpful. As stated above, the importance of CB1 receptors in 
protecting the organism against inflammation of the GI system
was demonstrated in a study where CB1 receptor-deficient mice
were more vulnerable, while FAAH-deficient mice were less
vulnerable to experimentally-induced colitis (105). 
Interestingly, adiponectin levels were increased in me-
senteric adipose tissue of patients with Crohn's disease, but 
not in patients with ulcerative colitis (140). Thus similarly to 
obesity, at least in Crohn's pathology too, ECs and adiponectin 
are counterbalanced. The putative significance of this finding
needs further investigation.
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Gastroesophageal reflux disease (GORD). This disorder 
results from a weak lower oesophagal sphincter causing gastric 
content to flow upward, hence symptoms including heartburn 
and acid regurgitation appear (124,141). The influence of
psychological stress, anxiety and depression on this condition 
has been shown (141-143). An CB-centered treatment may be 
developed either through central effects or through peripheral 
muscle relaxation. Indeed, cannabinoid CB1 receptor ago-
nists have been shown to relax the oesophageal sphincter in 
dogs and ferrets. This effects was mediated by vagal neural 
loops at peripheral and central (dorsal vagal complex) sites 
(85,92,97). 
Secretory diarrhea. Fluid-induced increase in stool 
volume, that is, secretory diarrhea, is caused by abnormal 
secretion and/or absorption of water and electrolytes as well 
as dysregulated intestinal motility (144,145). Psychological 
stress may precipitate secretory diarhoea, probably mediated 
by corticotrophin releasing hormone (CRH1) receptors (145). 
Activation of the HPA stress axis results in stress-induced 
secretory diarrhea (144). Stimulation of the ECBR system by 
the uptake inhibitor VDM11 reduced intestinal fluid accumu-
lation; conversely, the CB1 receptor antagonist rimonabant 
increased fluid accumulation (97). These observations suggest
that the ECs exert a tonic regulation of intestinal secretory 
activity which can be up-or down-regulated according to the 
(psycho)physiological environment. Further, cannabinoid CB1 
receptor activation resulted in decreased fluid accumulation in
the small intestine of the rat, suggesting that cannabinoid-based 
treatment may be beneficial for diarhoea (146).
Gastric ulcer. Summarizing a vast body of literature on 
the association between psychosocial factors (such as stress 
and the perception of stress) and peptic ulcers (36), Jones 
conservatively concludes that psychosocial factors may play 
a role in ulcer formation (147). Cannabinoid-induced reduc-
tion in gastric secretions and in ulcer formation has been 
observed many years ago and more recently, several reports 
have replicated and extended such observations to include the 
mediation by CB1 receptors in stomach and/or central loca-
tions (93,124,148). More specifically, Win 55,212 reduced
stress-induced ulcers in rats (148). From this study it is not 
clear whether the anti-stress effect was mediated centrally 
or peripherally. Possibly either or both routes are used under 
such conditions, since central stress-reducing effects of CBs 
have been shown (149), while the presence of CB1 receptors 
in (pre- and postganglionic) vagal pathways leading to the 
stomach (93) may have been activated as well.
Emesis. Antiemetic effects of (endo)cannabinod have 
been extensively demonstrated and several ∆9-THC-like can-
nabinoid drugs (the synthetic nabilone and dronabinol) are 
selectively available for oral clinical use (97,124,150,151). 
The antiemetic effects are mediated by CB1 receptor-medi-
ated responses on gastric vagal nerves or centrally via the area 
postrema and dorsal vagal complex (97). Taken together, it is 
widely agreed that CB-based drugs especially those which do 
not have central side effects, should be developed as antiemetic 
drugs for cancer and AIDS patients who receive chemothera-
peutic treatment. Cannabinoids may be especially effective 
in combating anticipatory nausea and vomiting (152). Since 
the area postrema has receptors located outside the CNS, CB1 
receptor-specific cannabinoids which are not active within the
CNS, should be particularly suitable (153,154). 
DEVELOPMENT
It is evident from the data summarized thus far, that the ECBR 
system is abundantly present and functionally important at 
all stages of ingestion and digestion in the adult organism. 
Although perhaps one of the very major systems (see also Table 
1), the ECBR system and its CB1 and CB2 receptors do not 
seem critical for survival, as most CB1 and/or CB2 knockout 
mice reach adulthood, be it with reduced body weights (155-
157). Similarly, very long term treatment (4 months) with the 
CB1 receptor antagonist rimonabant did not cause mortality or 
(overt) detrimental effects, except a robust reduction in body 
weight (about 8%) (158). In contrast, we have shown that a 
single injection with rimonabant administered within 24 h of 
birth in mice permanently interferes with milk ingestion, result-
ing in growth failure and death in many cases. The effect was 
dose dependent and was observed in several strains of mice 
(ICR, SABRA, C57BL/6). The growth stunting effect was not 
seen in CB1 receptor knockout pups but mortality was induced 
by rimonabant even in these knockouts, suggesting that these 
pups had developed a compensatory CB1-like (“CB3”) receptor 
(56,159,160). Further psychobiological analyses of rimona-
bant-treated neonates suggested that CB1 receptor activation 
in neonates is required for oral-motor development required 
for sucking (161). Since the behavioral and physiological defi-
ciencies of CB1 receptor-blocked mouse pups resemble infants 
suffering from “non-organic failure-to-thrive” (NOFTT), we 
have suggested that CB1 receptor-blocked neonates may be 
used as a model for NOFTT and form the basis for the devel-
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Localization in GIT Stomach, small intestine, colon Mainly stomach, much smaller 
amounts in small intestine 
22,100,122,174,175
Appetite/food intake Orexigenic orexigenic 74,175
Central/peripheral 
mechanism of food 
intake
Central (DVC, PVN/lateral 
hypothalamus) and peripheral
Central (arcutae nucleus, PVN) and 
peripheral
82,124,175,176
Colon Decreased secretion/motility enhanced motility 177
Ileum Relaxation/
Decreased secretion
No effect/decreased intestinal 
transit
177,178
Stomach Decreased acid secretion/delayed 
emptying






Inhibition of relaxation ? 85,92
Dorsal vagal complex Anti-emetic, GIT relaxation,
GIT decreased secretion










CNS Motor areas(?) Decreased locomotion Increased/decreased 
locomotion
14,181,182
Bone and cartilage 
homeostais
Bone (increased/decreased density) Bone and cartilage homeostasis 22,162,183
Immune system/
inflammation





anxiety Incease/decrease Increase 165,167
sleep Increase Increase/decrease 166,167
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opment of CB-based treatments.
CANNABINOID VERSUS GHRELIN
As stated above the ECBR system is ubiquitous and involved 
at many, if not all, levels of alimentary control and in many 
other functions. Interestingly, the recently discovered appeti-
tive hormone ghrelin which binds to GHS receptors and is 
largely synthesized in the stomach (as described above), also 
participates in alimentary control at a number of levels. In 
addition to their appetite stimulating qualities, ghrelin and 
the CBs have a number of functions in common, including 
modulation of bone homeostasis, anxiety, sleep regulation, 
anti-cancer potential and immune modulation (22,162-168). 
Moreover, direct interaction between the two systems in the 
hypothalamus mediating food intake, has been demonstrated 
(82). Thus the remarkable functional and anatomical overlap 
between ghrelin and the ECs is examined in Table 2. Inspection 
of this information reveals that despite the similarities between 
CBs and ghrelin, these systems also have opposite effects in 
a number of spheres including intestinal motility and gastric 
secretion and perhaps temperature control and motor activity 
(see Table 2 for references). 
In conclusion, ghrelin and CBs share a number of areas 
of influence in alimentary control and in other functions.
However, the overlap is not complete. Further investigations 
into the interactions between the two systems seem war-
ranted.
CONCLUSIONS AND FUTURE DIRECTIONS
Three major conclusions emanate from the material reviewed 
here: (i) the ECBR system is one of the major mediators be-
tween brain, the alimentary system and the adipose tissue, (ii) it 
is suggested that the role of the ECBR system in adult regula-
tion of digestion and ingestion is a remnant of its critical role 
for the initiation of feeding and survival in the newborn, and 
(iii) the pervasive influence of the ECBR system in alimentary
control make it a highly suitable target for therapeutic develop-
ments aimed at alleviating pathophysiological conditions such 
as IBD, IBS, gastric ulcers, nausea and anorexia. 
Especially manipulation of CB1 receptor activation will 
have therapeutic value in a number of alimentary pathophysi-
ological conditions. However CB1 receptor agonists often 
have undesirable psychoactive effects, such as confusion and 
anxiety. In view of the predominantly CB1 receptor-mediated 
effects on the GIT, it is desirable that CB-based treatment of GI 
disorders be mediated by ligands which do not cross the blood 
brain barrier or are not psychoactive for other reasons. We have 
recently demonstrated that several (+)cannabidiol derivates 
[such as (+)cannabidiol-demethyl heptyl and (+)carboxy-can-
nabidiol-demethyl heptyl], displayed CB1-receptor mediated 
inhibition of intestinal motility in the absence of central effects 
(153,154). Further studies on such compounds should address 
peripheral mechanisms of energy control including their effect 
on adipose tissue. 
Upregulating the ECBR system by the inhibition of enzy-
matic breakdown or reuptake inhibition is expected to yield 
more selective therapeutic effects. However, preventing EC 
degradation with oleamide, a fatty acid amide which is consid-
ered by most (169-172) not to bind CB1 receptors, resulted in 
psychoactive effects similar to those of AEA itself (169). On 
the other hand, a highly selective FAAH inhibitor URB597 is 
thought to have anxiolytic and antidepressant potential without 
sedative and addictive properties (173). 
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